Successful treatment of idiopathic anaphylaxis in an adolescent.
Pitt
Tracy J
TJ
Cisneros
Nestor
N
Kalicinsky
Chrystyna
C
Becker
Allan B
AB
D000293:Adolescent; D000322:Adrenergic Agonists / Q000008:administration & dosage*; D000707:Anaphylaxis / Q000188:drug therapy* / Q000209:etiology / Q000276:immunology / Q000473:pathology; D018926:Anti-Allergic Agents / Q000008:administration & dosage / Q000009:adverse effects; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects; D061067:Antibodies, Monoclonal, Humanized; D017332:Cetirizine / Q000008:administration & dosage / Q000009:adverse effects; D004837:Epinephrine / Q000008:administration & dosage*; D005260:Female; D006635:Histamine H2 Antagonists / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D008297:Male; D034721:Mastocytosis, Systemic / Q000188:drug therapy / Q000276:immunology / Q000473:pathology; D008875:Middle Aged; D000069444:Omalizumab; D011899:Ranitidine / Q000008:administration & dosage / Q000009:adverse effects; D014582:Urticaria Pigmentosa / Q000188:drug therapy / Q000276:immunology / Q000473:pathology
D000322:Adrenergic Agonists; D018926:Anti-Allergic Agents; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D006635:Histamine H2 Antagonists; D000069444:Omalizumab; D011899:Ranitidine; D004837:Epinephrine; D017332:Cetirizine